Biopharmaceutical company
3 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Insmed Incorporated in the last 30 days yet.
The 2 sources with the most insights about Insmed Incorporated on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Noted as being down for the year, with no investment thesis or recommendation.
Strong drug trajectory for Brensocatib, but high valuation suggests much of the upside is already priced in.
Mentioned as a liked small-cap biotech name that could be an M&A target. Noted to have pulled back from $212 to $175.
Noted as being down for the year, with no investment thesis or recommendation.
Strong drug trajectory for Brensocatib, but high valuation suggests much of the upside is already priced in.
Mentioned as a liked small-cap biotech name that could be an M&A target. Noted to have pulled back from $212 to $175.
Other assets that creators frequently mention in the same content as Insmed Incorporated.
The most active sources covering Insmed Incorporated (INSM) on Kazuha are @realmartinshkreli, RiskReversal Media. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about Insmed Incorporated (INSM) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Insmed Incorporated (INSM) most frequently also discuss XAU, NVO, BMY, NVDA, MU. See the "Discussed alongside" section above for full asset pages.